Squarepoint
AGRX

Squarepoint’s Agile Therapeutics AGRX Stock Holding History

Squarepoint’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-16
Closed -$43K – 3640
2021
Q2 		$43K Buy
+16
New +$52.8K ﹤0.01% 3116
2021
Q1 		– Sell
-57
Closed -$330K – 3784
2020
Q4 		$330K Buy
+57
New +$336K ﹤0.01% 2135
2020
Q3 		– Sell
-19
Closed -$108K – 2953
2020
Q2 		$108K Buy
+19
New +$98.7K ﹤0.01% 1996
2019
Q4 		– Sell
-24
Closed -$57K – 2907
2019
Q3 		$57K Buy
+24
New +$59.1K ﹤0.01% 2232
2018
Q1 		– Sell
-12
Closed -$63K – 2285
2017
Q4 		$63K Sell
12
-6
-33% -$55.9K ﹤0.01% 1998
2017
Q3 		$158K Buy
+18
New +$138K ﹤0.01% 1445

Other funds holding AGRX

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
NIM
Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Squarepoint's AGRX Position: Q3 2021 in Review

Squarepoint sold out of Agile Therapeutics (AGRX) in Q3 2021, closing a stake of 16 shares — an estimated $43K sold.

Squarepoint first reported a position in AGRX in Q3 2017 and held it in 6 quarters. The position peaked at $330K in Q4 2020. 49 funds tracked by Wall St. Rank hold AGRX as of Q3 2021.

  • Squarepoint reported no remaining Agile Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Squarepoint sold 16 Agile Therapeutics shares in Q3 2021, an estimated $43K.
  • Squarepoint first reported a position in Agile Therapeutics in Q3 2017 and held it in 6 quarters.
  • Squarepoint's Agile Therapeutics position peaked at $330K in Q4 2020.
  • 49 funds tracked by Wall St. Rank held Agile Therapeutics as of Q3 2021.

Based on Squarepoint's 13F filing for Q3 2021, filed 15 Nov 2021.